董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Myron Holubiak | 男 | Director and Executive Vice-Chairman | 78 | 250.61万美元 | 22.53 | 2026-01-28 |
| Leonard Mazur | 男 | Chief Executive Officer, Chairman, Secretary and Director | 80 | 450.79万美元 | 73.04 | 2026-01-28 |
| Suren Dutia | 男 | Director | 83 | 72.97万美元 | 2.00 | 2026-01-28 |
| Carol Webb | 女 | Director | 79 | 70.74万美元 | 2.10 | 2026-01-28 |
| Eugene Holuka | 男 | Director | 66 | 71.07万美元 | 2.06 | 2026-01-28 |
| Dennis M. McGrath | 男 | Director | 68 | 71.67万美元 | 1.10 | 2026-01-28 |
| Robert Smith | 男 | Director | 65 | 68.15万美元 | 0.80 | 2026-01-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Leonard Mazur | 男 | Chief Executive Officer, Chairman, Secretary and Director | 80 | 450.79万美元 | 73.04 | 2026-01-28 |
| Jaime Bartushak | 男 | Chief Business Officer and Chief Financial Officer | 58 | 80.90万美元 | 5.78 | 2026-01-28 |
| Myron S. Czuczman | 男 | Chief Medical Officer and Executive Vice President | 66 | 246.15万美元 | 5.60 | 2026-01-28 |
董事简历
中英对照 | 中文 | 英文- Myron Holubiak
-
Myron Holubiak是该公司的总裁兼首席执行官，自2015年10月起担任董事会成员。Holubiak先生还担任我们拥有多数股权的子公司Novecite，Inc.的代理首席执行官。Holubiak先生在管理和建议大型和新兴的制药和生命科学公司方面有着丰富的经验。Holubiak从1998年12月到2001年8月担任Roche Laboratories，Inc.（一家大型研究型制药公司）总裁。在此之前，他在罗氏工作了19年，担任过销售与市场营销职位。2002年9月至2016年7月，Holubiak先生担任BioScrip，Inc.（“；BioScrip”；）（纳斯达克市场代码:BIOS）的董事会主席。BioScrip是国内领先的输液和家庭护理管理解决方案提供商。自2010年7月以来，Holubiak先生一直担任AssemblyBiosciences，Inc.（“；Assembly”；）（纳斯达克市场代码:ASMB）及其前身Ventrus Biosciences，Inc.的董事会成员。Assembly公司是一家生物制药公司，开发治疗乙型肝炎病毒感染（HBV）和艰难梭菌相关性腹泻（CDAD）的创新疗法。此外，Holubiak先生担任BioAffinity Technologies Inc.的董事，这是一家私人控股公司。2013年3月，Holubiak先生创立了公司的全资子公司Leonard-Meron Biosciences，Inc.（“；LMB”；），并担任LMB的首席执行官兼总裁至2016年3月。此外，Holubiak先生还于2013年4月至2015年4月担任Academy of Managed Care Pharmacy Foundation的受托人。Holubiak先生在匹兹堡大学（University of Pittsburgh）获得分子生物学和生物物理学学士学位；在哈佛商学院（Harvard Business School）和伦敦大学（University of London）获得高级商业培训；在约克大学（University of York）卫生经济学中心（Centre for Health Economics）获得卫生经济学高级培训。
Myron Holubiak is the Executive Vice Chairman of the Company, a position he has held since May 2022, and has been a member of the Board of Directors since October 2015. From October 2015 through April 2022, Mr. Holubiak served as President and Chief Executive Officer. Mr. Holubiak also serves as Secretary and member of the board of directors of majority owned subsidiary, Citi Oncology, and as the acting Chief Executive Officer of majority owned subsidiary, NoveCite. Mr. Holubiak has extensive experience in managing and advising large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. ("Roche"), a major research based pharmaceutical company, from December 1998 to Augt 2001. Prior to that, he held sales and marketing positions at Roche during his 19 year tenure. From September 2002 to July 2016, Mr. Holubiak served on the board of directors and for the last two years was the Chairman of the board of directors of BioScrip, Inc. (merged with Option Care Health in 2019), a leading national provider of infion and home care management solutions. Additionally, Mr. Holubiak formerly served as a member of the board of directors of Assembly Biosciences, Inc. ("Assembly") (Nasdaq: ASMB) and its predecessor Ventr Biosciences, Inc. Assembly is a biopharmaceutical company developing innovative, small molecule therapeutics for hepatitis B vir (HBV), hepatitis delta vir (HDV) and herpes vir infections. In March 2013, Mr. Holubiak founded LMB, the Company's wholly owned subsidiary, and he served as the Chief Executive Officer and President of LMB until March 2016. In addition, Mr. Holubiak was also a trtee of the Academy of Managed Care Pharmacy Foundation from April 2013 to April 2015. Mr. Holubiak received a B.S. in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced biness training from the Harvard Biness School and the University of London; and advanced training in health economics from the University of York's Centre for Health Economics. - Myron Holubiak是该公司的总裁兼首席执行官，自2015年10月起担任董事会成员。Holubiak先生还担任我们拥有多数股权的子公司Novecite，Inc.的代理首席执行官。Holubiak先生在管理和建议大型和新兴的制药和生命科学公司方面有着丰富的经验。Holubiak从1998年12月到2001年8月担任Roche Laboratories，Inc.（一家大型研究型制药公司）总裁。在此之前，他在罗氏工作了19年，担任过销售与市场营销职位。2002年9月至2016年7月，Holubiak先生担任BioScrip，Inc.（“；BioScrip”；）（纳斯达克市场代码:BIOS）的董事会主席。BioScrip是国内领先的输液和家庭护理管理解决方案提供商。自2010年7月以来，Holubiak先生一直担任AssemblyBiosciences，Inc.（“；Assembly”；）（纳斯达克市场代码:ASMB）及其前身Ventrus Biosciences，Inc.的董事会成员。Assembly公司是一家生物制药公司，开发治疗乙型肝炎病毒感染（HBV）和艰难梭菌相关性腹泻（CDAD）的创新疗法。此外，Holubiak先生担任BioAffinity Technologies Inc.的董事，这是一家私人控股公司。2013年3月，Holubiak先生创立了公司的全资子公司Leonard-Meron Biosciences，Inc.（“；LMB”；），并担任LMB的首席执行官兼总裁至2016年3月。此外，Holubiak先生还于2013年4月至2015年4月担任Academy of Managed Care Pharmacy Foundation的受托人。Holubiak先生在匹兹堡大学（University of Pittsburgh）获得分子生物学和生物物理学学士学位；在哈佛商学院（Harvard Business School）和伦敦大学（University of London）获得高级商业培训；在约克大学（University of York）卫生经济学中心（Centre for Health Economics）获得卫生经济学高级培训。
- Myron Holubiak is the Executive Vice Chairman of the Company, a position he has held since May 2022, and has been a member of the Board of Directors since October 2015. From October 2015 through April 2022, Mr. Holubiak served as President and Chief Executive Officer. Mr. Holubiak also serves as Secretary and member of the board of directors of majority owned subsidiary, Citi Oncology, and as the acting Chief Executive Officer of majority owned subsidiary, NoveCite. Mr. Holubiak has extensive experience in managing and advising large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. ("Roche"), a major research based pharmaceutical company, from December 1998 to Augt 2001. Prior to that, he held sales and marketing positions at Roche during his 19 year tenure. From September 2002 to July 2016, Mr. Holubiak served on the board of directors and for the last two years was the Chairman of the board of directors of BioScrip, Inc. (merged with Option Care Health in 2019), a leading national provider of infion and home care management solutions. Additionally, Mr. Holubiak formerly served as a member of the board of directors of Assembly Biosciences, Inc. ("Assembly") (Nasdaq: ASMB) and its predecessor Ventr Biosciences, Inc. Assembly is a biopharmaceutical company developing innovative, small molecule therapeutics for hepatitis B vir (HBV), hepatitis delta vir (HDV) and herpes vir infections. In March 2013, Mr. Holubiak founded LMB, the Company's wholly owned subsidiary, and he served as the Chief Executive Officer and President of LMB until March 2016. In addition, Mr. Holubiak was also a trtee of the Academy of Managed Care Pharmacy Foundation from April 2013 to April 2015. Mr. Holubiak received a B.S. in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced biness training from the Harvard Biness School and the University of London; and advanced training in health economics from the University of York's Centre for Health Economics.
- Leonard Mazur
-
Leonard Mazur是该公司的执行主席兼秘书，自2014年9月起担任董事会成员。Mazur先生还担任我们持有多数股权的子公司Novecite，Inc.的秘书，并为Novecite提供其他指导。Mazur先生是Akrimax Pharmaceuticals，LLC“；Akrimax”；的联合创始人兼副董事长，该公司是一家私人控股的制药公司，专门生产心血管和通用制药产品。Akrimax成立于2008年9月，在从主要制药公司收购药物的同时成功推出处方药。从2005年1月到2012年5月，Mazur先生共同创立并担任Triax Pharmaceuticals LLC（“；Triax”；）的首席运营官，这是一家专业制药公司，生产处方皮肤病药物。加入Triax之前，他从1995年到2005年担任Genesis Pharmaceutical，Inc.（“；Genesis”；）的创始人和首席执行官，该公司是一家皮肤科产品公司，通过皮肤科医生办公室销售其产品，并为主要制药公司共同推广产品。Mazur先生于2003年成功地将Genesis出售给Pierre Fabre，这是一家领先的制药公司。Mazur先生在Medicis Pharmaceutical Corporation担任执行Vice President、ICN Pharmaceuticals，Inc.担任Vice President、销售和市场营销、Knoll Pharma（巴斯夫公司的一个部门）和Cooper Laboratories，Inc.拥有丰富的销售、市场营销和业务发展经验。Mazur先生是Manor College的董事会成员，是Ellis Island Medal of Honor的获得者，之前是公司全资子公司LMB的董事会主席。Mazur先生从坦普尔大学（Temple University）获得学士学位和工商管理硕士学位，并曾在美国海军陆战队预备役部队服役。
Leonard Mazur is the Executive Chairman and Secretary of the Company and has been a member of the Board of Directors since September 2014 and in May 2022 became the Chief Executive Officer. Mr. Mazur also serves as and President and Chief Executive Officer and member of the board of directors of majority owned subsidiary, Citi Oncology, Inc. (Nasdaq: CTOR) ("Citi Oncology"), and as the Secretary of majority owned subsidiary, NoveCite, Inc. ("NoveCite"), and provides other guidance to Citi Oncology and NoveCite. From Augt 2021 to June 2025, Mr. Mazur served on the board of directors of Tharimmune, Inc. (formerly Hillstream BioPharma, Inc.) (Nasdaq: THAR), a pre clinical biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. Mr. Mazur was the co founder and Vice Chairman of Akrimax Pharmaceuticals, LLC ("Akrimax"), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products, from its founding in 2008 until its sale in 2018. From January 2005 to May 2012, Mr. Mazur co founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC ("Triax"), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. ("Genesis"), a dermatological products company that marketed its products through dermatologists' offices as ll as co promoting products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and biness development experience from his tenures at Medicis Pharmaceutical Corporation as Executive Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc. Mr. Mazur is a member of the Board of Trtees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previoly the Chairman of the board of directors of Leonard Meron Biosciences, Inc. ("LMB"), the Company's wholly owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from Temple University and has served in the U.S. Marine Corps Reserves. - Leonard Mazur是该公司的执行主席兼秘书，自2014年9月起担任董事会成员。Mazur先生还担任我们持有多数股权的子公司Novecite，Inc.的秘书，并为Novecite提供其他指导。Mazur先生是Akrimax Pharmaceuticals，LLC“；Akrimax”；的联合创始人兼副董事长，该公司是一家私人控股的制药公司，专门生产心血管和通用制药产品。Akrimax成立于2008年9月，在从主要制药公司收购药物的同时成功推出处方药。从2005年1月到2012年5月，Mazur先生共同创立并担任Triax Pharmaceuticals LLC（“；Triax”；）的首席运营官，这是一家专业制药公司，生产处方皮肤病药物。加入Triax之前，他从1995年到2005年担任Genesis Pharmaceutical，Inc.（“；Genesis”；）的创始人和首席执行官，该公司是一家皮肤科产品公司，通过皮肤科医生办公室销售其产品，并为主要制药公司共同推广产品。Mazur先生于2003年成功地将Genesis出售给Pierre Fabre，这是一家领先的制药公司。Mazur先生在Medicis Pharmaceutical Corporation担任执行Vice President、ICN Pharmaceuticals，Inc.担任Vice President、销售和市场营销、Knoll Pharma（巴斯夫公司的一个部门）和Cooper Laboratories，Inc.拥有丰富的销售、市场营销和业务发展经验。Mazur先生是Manor College的董事会成员，是Ellis Island Medal of Honor的获得者，之前是公司全资子公司LMB的董事会主席。Mazur先生从坦普尔大学（Temple University）获得学士学位和工商管理硕士学位，并曾在美国海军陆战队预备役部队服役。
- Leonard Mazur is the Executive Chairman and Secretary of the Company and has been a member of the Board of Directors since September 2014 and in May 2022 became the Chief Executive Officer. Mr. Mazur also serves as and President and Chief Executive Officer and member of the board of directors of majority owned subsidiary, Citi Oncology, Inc. (Nasdaq: CTOR) ("Citi Oncology"), and as the Secretary of majority owned subsidiary, NoveCite, Inc. ("NoveCite"), and provides other guidance to Citi Oncology and NoveCite. From Augt 2021 to June 2025, Mr. Mazur served on the board of directors of Tharimmune, Inc. (formerly Hillstream BioPharma, Inc.) (Nasdaq: THAR), a pre clinical biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. Mr. Mazur was the co founder and Vice Chairman of Akrimax Pharmaceuticals, LLC ("Akrimax"), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products, from its founding in 2008 until its sale in 2018. From January 2005 to May 2012, Mr. Mazur co founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC ("Triax"), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. ("Genesis"), a dermatological products company that marketed its products through dermatologists' offices as ll as co promoting products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and biness development experience from his tenures at Medicis Pharmaceutical Corporation as Executive Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc. Mr. Mazur is a member of the Board of Trtees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previoly the Chairman of the board of directors of Leonard Meron Biosciences, Inc. ("LMB"), the Company's wholly owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from Temple University and has served in the U.S. Marine Corps Reserves.
- Suren Dutia
-
Suren Dutia自2015年10月起担任董事会成员。Dutia先生从2011年3月开始担任尤因·马里奥·考夫曼基金会（Ewing Mario Kauffman Foundation）的高级研究员，并从2013年开始担任圣路易斯华盛顿大学（Washington University，St.Louis）Skandalaris创业研究中心的高级研究员。他曾一直担任Center for Digital Transformation，University of California，Irvine的顾问委员会成员（2012年5月以来），以及AccelPath，LLC的董事会主席（2009年10月以来）。从2006年2月到2010年5月，Dutia先生担任TIE Global的首席执行官，这是一家参与全球促进创业的非营利组织。从2011年2月到2013年5月，他曾担任LifeProof Cases公司的董事，也曾担任Anvita Health公司的董事（从2000年7月到2011年12月）。Dutia从1989年到1998年担任Xscribe Corporation首席执行官和董事会主席。在Xscribe Corporation任职之前，Dutia先生在Dynatech Corporation担任过几个职位，此外，他还是一家医疗仪器公司的总裁。此前，Dutia先生在美国教育部（U.S.Department of Education）任职。Dutia先生在圣路易斯华盛顿大学（Washington University，St.Louis）获得化学工程学士学位和硕士学位以及政治学学士学位。此外，他在University of Dallas获得工商管理硕士学位。
Suren Dutia has been a member of the Board of Directors since October 2015. In addition to his role as an outside independent director of Citi Pharma, Mr. Dutia has been serving as director of Flint Rehab and Vahan Inc, since 2016. Mr. Dutia has been involved in fostering entrepreneurship for more than 20 years and served as Senior Fellow of the Ewing Marion Kauffman Foundation from March 2011 to December 2016 and Senior Fellow of Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship at Washington University, St. Louis from 2010 to 2013. He has served as a member of the advisory board of Center for Digital Transformation, University of California, Irvine since May 2012. From February 2006 to May 2010, Mr. Dutia served as the Chief Executive Officer of TiE, a non profit organization involved in fostering entrepreneurship globally. From February 2011 to May 2013, Mr. Dutia served as a director of LifeProof and from July 2000 to December 2011, he served as a director of Anvita Health. From 1989 to 1998, Mr. Dutia served as the Chief Executive Officer and Chairman of the board of directors of Xscribe Corporation. Prior to his positions with Xscribe Corporation, Mr. Dutia held several positions with Dynatech Corporation, and, in addition, he was the President of a medical instruments company. Mr. Dutia received his B.S. and M.S. degrees in chemical engineering and B.A. in political science from Washington University, St. Louis. In addition, he obtained an M.B.A. from the University of Dallas. - Suren Dutia自2015年10月起担任董事会成员。Dutia先生从2011年3月开始担任尤因·马里奥·考夫曼基金会（Ewing Mario Kauffman Foundation）的高级研究员，并从2013年开始担任圣路易斯华盛顿大学（Washington University，St.Louis）Skandalaris创业研究中心的高级研究员。他曾一直担任Center for Digital Transformation，University of California，Irvine的顾问委员会成员（2012年5月以来），以及AccelPath，LLC的董事会主席（2009年10月以来）。从2006年2月到2010年5月，Dutia先生担任TIE Global的首席执行官，这是一家参与全球促进创业的非营利组织。从2011年2月到2013年5月，他曾担任LifeProof Cases公司的董事，也曾担任Anvita Health公司的董事（从2000年7月到2011年12月）。Dutia从1989年到1998年担任Xscribe Corporation首席执行官和董事会主席。在Xscribe Corporation任职之前，Dutia先生在Dynatech Corporation担任过几个职位，此外，他还是一家医疗仪器公司的总裁。此前，Dutia先生在美国教育部（U.S.Department of Education）任职。Dutia先生在圣路易斯华盛顿大学（Washington University，St.Louis）获得化学工程学士学位和硕士学位以及政治学学士学位。此外，他在University of Dallas获得工商管理硕士学位。
- Suren Dutia has been a member of the Board of Directors since October 2015. In addition to his role as an outside independent director of Citi Pharma, Mr. Dutia has been serving as director of Flint Rehab and Vahan Inc, since 2016. Mr. Dutia has been involved in fostering entrepreneurship for more than 20 years and served as Senior Fellow of the Ewing Marion Kauffman Foundation from March 2011 to December 2016 and Senior Fellow of Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship at Washington University, St. Louis from 2010 to 2013. He has served as a member of the advisory board of Center for Digital Transformation, University of California, Irvine since May 2012. From February 2006 to May 2010, Mr. Dutia served as the Chief Executive Officer of TiE, a non profit organization involved in fostering entrepreneurship globally. From February 2011 to May 2013, Mr. Dutia served as a director of LifeProof and from July 2000 to December 2011, he served as a director of Anvita Health. From 1989 to 1998, Mr. Dutia served as the Chief Executive Officer and Chairman of the board of directors of Xscribe Corporation. Prior to his positions with Xscribe Corporation, Mr. Dutia held several positions with Dynatech Corporation, and, in addition, he was the President of a medical instruments company. Mr. Dutia received his B.S. and M.S. degrees in chemical engineering and B.A. in political science from Washington University, St. Louis. In addition, he obtained an M.B.A. from the University of Dallas.
- Carol Webb
-
Carol Webb自2014年3月17日起担任LMB的董事，并在2016年3月LMB&8217；s被公司收购后担任公司董事。从2000年到2005年，她担任强生公司公司集团主席。从1987年到2000年，她曾担任Ortho Biotech公司的多种职务，包括总裁、Vice President、执行董事、产品管理和高级产品董事。从1972年到1983年，Webb女士在罗氏实验室（Roche Laboratories）担任多个职位，包括销售代表，销售培训师，产品经理和公共政策经理。Webb女士在鲍灵格林州立大学（Bowling Green State University）获得生物学学士学位。
Carol Webb served as a director of LMB beginning March 17, 2014 and, upon LMB's acquisition by the Company in March 2016, has been a member of the Board of Directors of the Company. From 2000 to 2005, she served as Company Group Chairman of Johnson & Johnson. From 1987 to 2000, she served in vario capacities at Ortho Biotech, including President, Vice President, Executive Director, Product Management and Senior Product Director. From 1972 to 1983, Ms. bb worked in vario positions at Roche Laboratories, including Sales Representative, Sales Trainer, Product Manager and Manager of Public Policy. Ms. bb received her B.S. in Biology from Bowling Green State University. - Carol Webb自2014年3月17日起担任LMB的董事，并在2016年3月LMB&8217；s被公司收购后担任公司董事。从2000年到2005年，她担任强生公司公司集团主席。从1987年到2000年，她曾担任Ortho Biotech公司的多种职务，包括总裁、Vice President、执行董事、产品管理和高级产品董事。从1972年到1983年，Webb女士在罗氏实验室（Roche Laboratories）担任多个职位，包括销售代表，销售培训师，产品经理和公共政策经理。Webb女士在鲍灵格林州立大学（Bowling Green State University）获得生物学学士学位。
- Carol Webb served as a director of LMB beginning March 17, 2014 and, upon LMB's acquisition by the Company in March 2016, has been a member of the Board of Directors of the Company. From 2000 to 2005, she served as Company Group Chairman of Johnson & Johnson. From 1987 to 2000, she served in vario capacities at Ortho Biotech, including President, Vice President, Executive Director, Product Management and Senior Product Director. From 1972 to 1983, Ms. bb worked in vario positions at Roche Laboratories, including Sales Representative, Sales Trainer, Product Manager and Manager of Public Policy. Ms. bb received her B.S. in Biology from Bowling Green State University.
- Eugene Holuka
-
Eugene Holuka自2016年6月起担任公司董事。Holuka博士是一名内科医生，在重症监护医学领域执业近30年。他目前是斯塔滕岛大学医院（the Staten Island University Hospital）的主治医生，在那里他自1991年以来一直执业。Holuka博士自2011年以来还担任Touro College of Osteopathic Medicine的兼职临床助理教授。从2014年4月到2016年3月公司收购LMB，他曾担任LMB科学顾问委员会的成员。Holuka博士于2000年获得埃利斯岛荣誉勋章（Ellis Island Medal of Honor），并自2005年以来在NECO委员会董事会任职。2000年至2008年，他是Forum&8217；s Children Foundation的执行委员会成员。
Eugene Holuka has been a member of the Board of Directors since June 2016. Dr. Holuka is an internist and has practiced in internal medicine for almost 35 years. He is presently an attending physician at the Staten Island University Hospital where he has practiced since 1991. Dr. Holuka has also served as an Adjunct Clinical Assistant Professor at the To College of Osteopathic Medicine since 2011 and currently serves as an associate professor at the Zucker School of Medicine at Hofstra University. From April 2014 until the acquisition of LMB by the Company in March 2016, he was a member of the LMB Scientific Advisory Board. Dr. Holuka received the Ellis Island Medal of Honor in 2000 and has served on the NECO Committee Board since 2005. He was an Executive Committee Member on the Forum's Children Foundation from 2000 until 2008. - Eugene Holuka自2016年6月起担任公司董事。Holuka博士是一名内科医生，在重症监护医学领域执业近30年。他目前是斯塔滕岛大学医院（the Staten Island University Hospital）的主治医生，在那里他自1991年以来一直执业。Holuka博士自2011年以来还担任Touro College of Osteopathic Medicine的兼职临床助理教授。从2014年4月到2016年3月公司收购LMB，他曾担任LMB科学顾问委员会的成员。Holuka博士于2000年获得埃利斯岛荣誉勋章（Ellis Island Medal of Honor），并自2005年以来在NECO委员会董事会任职。2000年至2008年，他是Forum&8217；s Children Foundation的执行委员会成员。
- Eugene Holuka has been a member of the Board of Directors since June 2016. Dr. Holuka is an internist and has practiced in internal medicine for almost 35 years. He is presently an attending physician at the Staten Island University Hospital where he has practiced since 1991. Dr. Holuka has also served as an Adjunct Clinical Assistant Professor at the To College of Osteopathic Medicine since 2011 and currently serves as an associate professor at the Zucker School of Medicine at Hofstra University. From April 2014 until the acquisition of LMB by the Company in March 2016, he was a member of the LMB Scientific Advisory Board. Dr. Holuka received the Ellis Island Medal of Honor in 2000 and has served on the NECO Committee Board since 2005. He was an Executive Committee Member on the Forum's Children Foundation from 2000 until 2008.
- Dennis M. McGrath
-
Dennis M. McGrath于2019年3月起担任PAVmed（纳斯达克股票代码：PAVM）——一家处于多元化商业阶段的医疗技术公司——的总裁（于2017年3月至2019年3月担任副总裁执行Dennis M. McGrath），并于2017年3月起担任PAVmed的首席财务官首席财务官。自Lucid完成首次公开募股后，McGrath先生还担任过Lucid的首席财务官，Lucid是PAVmed的控股子公司。在此之前，McGrath先生于2000年至2017年在PhotoMedex，Inc.（前身为Nasdaq：PHMD）担任多个高级职位，该公司是一家全球医疗设备和服务制造商和分销商，包括于2011年至2017年担任董事、总裁兼首席财务官。在PhotoMedex于2011年12月与Radiancy，Inc反向收购之前，他还曾于2009年至2011年担任董事会成员兼首席执行官，并于2000年至2009年担任财务副总裁兼首席财务官。他以P.A.C.（费城资本与技术联盟）入围2011年度最佳投资交易、SmartCEO杂志2012年度最佳转型公司首席执行官、安永2013年度最佳企业家入围等荣誉获奖。他在国内和国际并购方面拥有丰富的经验，特别是涉及上市公司收购的并购，包括Surgical Laser Technologies，Inc（原纳斯达克代码：SLTI）、ProCyte Corporation（原纳斯达克代码：PRCY）、LCA Vision，Inc.（原纳斯达克代码：LCAV）和Think New Ideas，Inc.（原纳斯达克代码：THNK）。在加入PhotoMedex之前，他曾在商业咨询和技术整合公司AnswerThink Consulting Group，Inc.（当时的纳斯达克股票代码：ANSR，现在的哈克特集团，纳斯达克股票代码：HCKT）担任多个高级职位，其中1999年至2000年担任AnswerThink Consulting Group，Inc.最大部门Internet Practice的首席运营官，在两家公司合并期间，他同时担任Think New Ideas，Inc.（当时的纳斯达克股票代码：THNK，现纳斯达克股票代码：HCKT）的代理首席财务官，这是一家交互式营销服务和商业解决方案公司。McGrath先生还于1996年至1999年担任TriSpan，Inc.的首席财务官、执行副总裁兼董事。TriSpan，Inc.是一家互联网商务解决方案和技术咨询公司，该公司于1999年被AnswerThink Consulting Group，Inc.收购。在Arthur Andersen & Co.任职期间，他开始了自己的职业生涯，1981年成为一名注册会计师，并以优异成绩获得拉萨尔大学会计学学士学位。此外，他还担任审计和薪酬委员会主席以及多家医疗器械公司的董事，包括DarioHealth Corp.（Nasdaq：DRIO）、Cagent Vascular，LLC和BioVector，Inc。McGrath先生曾于2007年至2009年担任Embrella Cardiovascular，Inc.（出售给Edwards Lifesciences Corporation，NYSE：EW）的董事。他还担任泰勒大学访客委员会成员和马诺学院董事会主席。
Dennis M. McGrath has been a member of the Board of Directors since February 2023. He has served as the President of PAVmed, Inc. (Nasdaq: PAVM), a diversified commercial stage medical technology company since March 2019 (having served as Executive Vice President from March 2017 to March 2019) and as PAVmed's Chief Financial Officer since March 2017. Mr. McGrath has also served as the Chief Financial Officer of Lucid Diagnostics Inc (Nasdaq: LUCD), PAVmed's majority owned subsidiary since the consummation of Lucid's initial public offering. Previoly, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (formerly, Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex's reverse merger with Radiancy, Inc in December 2011, he also served as a board member and Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011 Investment Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst & Young 2013 Entrepreneur of the Year.In addition, he serves as the audit and compensation committee chair and a director of several medical device companies, including DarioHealth Corp. (Nasdaq: DRIO), and LIV Process, formerly BioVector, Inc. Previoly from 2014 to 2024, Mr. McGrath served as a director and audit chair of Cagent Vascular, Inc., and from 2007 to 2009, Mr. McGrath served as a director of Embrella Cardiovascular, Inc. (sold to Edwards Lifesciences Corporation, NYSE: EW). He also serves on the Board of Visitors for Taylor University and on Board of Trtees of Manor College. - Dennis M. McGrath于2019年3月起担任PAVmed（纳斯达克股票代码：PAVM）——一家处于多元化商业阶段的医疗技术公司——的总裁（于2017年3月至2019年3月担任副总裁执行Dennis M. McGrath），并于2017年3月起担任PAVmed的首席财务官首席财务官。自Lucid完成首次公开募股后，McGrath先生还担任过Lucid的首席财务官，Lucid是PAVmed的控股子公司。在此之前，McGrath先生于2000年至2017年在PhotoMedex，Inc.（前身为Nasdaq：PHMD）担任多个高级职位，该公司是一家全球医疗设备和服务制造商和分销商，包括于2011年至2017年担任董事、总裁兼首席财务官。在PhotoMedex于2011年12月与Radiancy，Inc反向收购之前，他还曾于2009年至2011年担任董事会成员兼首席执行官，并于2000年至2009年担任财务副总裁兼首席财务官。他以P.A.C.（费城资本与技术联盟）入围2011年度最佳投资交易、SmartCEO杂志2012年度最佳转型公司首席执行官、安永2013年度最佳企业家入围等荣誉获奖。他在国内和国际并购方面拥有丰富的经验，特别是涉及上市公司收购的并购，包括Surgical Laser Technologies，Inc（原纳斯达克代码：SLTI）、ProCyte Corporation（原纳斯达克代码：PRCY）、LCA Vision，Inc.（原纳斯达克代码：LCAV）和Think New Ideas，Inc.（原纳斯达克代码：THNK）。在加入PhotoMedex之前，他曾在商业咨询和技术整合公司AnswerThink Consulting Group，Inc.（当时的纳斯达克股票代码：ANSR，现在的哈克特集团，纳斯达克股票代码：HCKT）担任多个高级职位，其中1999年至2000年担任AnswerThink Consulting Group，Inc.最大部门Internet Practice的首席运营官，在两家公司合并期间，他同时担任Think New Ideas，Inc.（当时的纳斯达克股票代码：THNK，现纳斯达克股票代码：HCKT）的代理首席财务官，这是一家交互式营销服务和商业解决方案公司。McGrath先生还于1996年至1999年担任TriSpan，Inc.的首席财务官、执行副总裁兼董事。TriSpan，Inc.是一家互联网商务解决方案和技术咨询公司，该公司于1999年被AnswerThink Consulting Group，Inc.收购。在Arthur Andersen & Co.任职期间，他开始了自己的职业生涯，1981年成为一名注册会计师，并以优异成绩获得拉萨尔大学会计学学士学位。此外，他还担任审计和薪酬委员会主席以及多家医疗器械公司的董事，包括DarioHealth Corp.（Nasdaq：DRIO）、Cagent Vascular，LLC和BioVector，Inc。McGrath先生曾于2007年至2009年担任Embrella Cardiovascular，Inc.（出售给Edwards Lifesciences Corporation，NYSE：EW）的董事。他还担任泰勒大学访客委员会成员和马诺学院董事会主席。
- Dennis M. McGrath has been a member of the Board of Directors since February 2023. He has served as the President of PAVmed, Inc. (Nasdaq: PAVM), a diversified commercial stage medical technology company since March 2019 (having served as Executive Vice President from March 2017 to March 2019) and as PAVmed's Chief Financial Officer since March 2017. Mr. McGrath has also served as the Chief Financial Officer of Lucid Diagnostics Inc (Nasdaq: LUCD), PAVmed's majority owned subsidiary since the consummation of Lucid's initial public offering. Previoly, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (formerly, Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex's reverse merger with Radiancy, Inc in December 2011, he also served as a board member and Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011 Investment Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst & Young 2013 Entrepreneur of the Year.In addition, he serves as the audit and compensation committee chair and a director of several medical device companies, including DarioHealth Corp. (Nasdaq: DRIO), and LIV Process, formerly BioVector, Inc. Previoly from 2014 to 2024, Mr. McGrath served as a director and audit chair of Cagent Vascular, Inc., and from 2007 to 2009, Mr. McGrath served as a director of Embrella Cardiovascular, Inc. (sold to Edwards Lifesciences Corporation, NYSE: EW). He also serves on the Board of Visitors for Taylor University and on Board of Trtees of Manor College.
- Robert Smith
-
Robert Smith是一位多才多艺的生物制药高管，已在领先的制药公司推动商业、财务和运营方面的成功，其中包括辉瑞公司（NYSE：PFE）和惠氏（前NYSE：WYE），任职超过35年。史密斯先生在业务发展、并购、企业和商业战略以及研发领域数十年的行政领导角色磨练了他广泛的行业专业知识。在过去八年中（2016年5月至2024年1月），Smith先生担任辉瑞全球基因治疗业务高级副总裁，负责管理和领导其基因治疗业务以及与罕见病研究单位合作开展的罕见病早期商业开发活动。在辉瑞任职期间，Smith先生还曾担任业务发展高级副总裁（2009年10月至2016年5月），并领导支持其全球研发组织的业务发展和战略交易团队。在辉瑞任职期间，他还领导过辉瑞全球动物健康、辉瑞以前的子公司Capsugel、消费者医疗保健和营养业务部门的业务发展和战略团队，以及支持辉瑞所有全球生物制药业务部门和全球研发组织的联盟管理职能。Smith先生于2009年从惠氏制药加入辉瑞，此前跟随辉瑞收购惠氏，担任并购事务高级副总裁（2008年4月至2009年10月），负责领导和管理惠氏的全球并购集团。在此之前，在惠氏担任全球授权高级副总裁期间，他完成了大量支持惠氏商业和研发部门的交易。Smith先生曾担任私营公司AM Pharma B.V.（观察员）、Bamboo Therapeutics Inc.（2016年1月至2016年8月）、Ignite Immunotherapeutics Inc.（2016年12月至2019年10月）以及Iterum Therapeutics Limited（观察员）（纳斯达克：ITRM）的董事会成员。Smith先生还担任或曾经担任Life Sciences PA –宾夕法尼亚州生物技术协会、Bio NJ –新泽西州生物技术协会（自2021年起）、Duke Margolis Value Based Agreements Advisory Board、再生医学联盟（ARM）（自2018年起）和细胞与基因医学基金会（FCGM）（自2019年起）的成员。他是ARM和FCGM董事会执行委员会成员，并担任ARM董事会治理和运营委员会主席。Smith先生还是Ocugen, Inc.商业顾问委员会、威斯康星州麦迪逊市风险投资者有限责任公司投资咨询委员会以及弗吉尼亚州夏洛茨维尔焦点超声基金会细胞和基因治疗科学顾问委员会的成员。Smith先生在罗切斯特大学获得神经科学学士学位，在纽约州罗切斯特的罗切斯特大学William E. Simon工商管理研究生院获得金融和企业会计工商管理硕士学位。
Robert Smith has been a member of the Board of Directors since March 2024. Mr. Smith is an accomplished biopharmaceutical executive who has driven commercial, financial, and operational success at leading pharmaceutical companies, including Pfizer Inc. (NYSE: PFE) and Wyeth Pharmaceuticals (formerly NYSE: WYE), for more than 35 years. Mr. Smith's extensive indtry expertise has been honed by decades of executive leadership roles in biness development, mergers and acquisitions, corporate and commercial strategy, and research and development. For the past eight years (May 2016 to January 2024), Mr. Smith served as Senior Vice President, Global Gene Therapy Biness of Pfizer and was responsible for managing and leading gene therapy and rare disease early commercial development activities in partnership with the rare disease research unit. He is a member of the Executive Committees of the ARM and FCGM Board of Directors and serves as the Chairman of the ARM Board's Governance and Operations Committee. Mr. Smith is also a member of the Biness Advisory Board of Ocugen, Inc., the Investment Advisory Committee for Venture Investors LLC, Madison, Wisconsin, and the Cell and Gene Therapy Scientific Advisory Board of the Foced Ultrasound Foundation based in Charlottesville, Virginia. Mr. Smith obtained a B.S. in Neuroscience from the University of Rochester and an M.B.A. in Finance and Corporate Accounting from the William E. Simon Graduate School of Biness Administration at the University of Rochester, Rochester, New York. - Robert Smith是一位多才多艺的生物制药高管，已在领先的制药公司推动商业、财务和运营方面的成功，其中包括辉瑞公司（NYSE：PFE）和惠氏（前NYSE：WYE），任职超过35年。史密斯先生在业务发展、并购、企业和商业战略以及研发领域数十年的行政领导角色磨练了他广泛的行业专业知识。在过去八年中（2016年5月至2024年1月），Smith先生担任辉瑞全球基因治疗业务高级副总裁，负责管理和领导其基因治疗业务以及与罕见病研究单位合作开展的罕见病早期商业开发活动。在辉瑞任职期间，Smith先生还曾担任业务发展高级副总裁（2009年10月至2016年5月），并领导支持其全球研发组织的业务发展和战略交易团队。在辉瑞任职期间，他还领导过辉瑞全球动物健康、辉瑞以前的子公司Capsugel、消费者医疗保健和营养业务部门的业务发展和战略团队，以及支持辉瑞所有全球生物制药业务部门和全球研发组织的联盟管理职能。Smith先生于2009年从惠氏制药加入辉瑞，此前跟随辉瑞收购惠氏，担任并购事务高级副总裁（2008年4月至2009年10月），负责领导和管理惠氏的全球并购集团。在此之前，在惠氏担任全球授权高级副总裁期间，他完成了大量支持惠氏商业和研发部门的交易。Smith先生曾担任私营公司AM Pharma B.V.（观察员）、Bamboo Therapeutics Inc.（2016年1月至2016年8月）、Ignite Immunotherapeutics Inc.（2016年12月至2019年10月）以及Iterum Therapeutics Limited（观察员）（纳斯达克：ITRM）的董事会成员。Smith先生还担任或曾经担任Life Sciences PA –宾夕法尼亚州生物技术协会、Bio NJ –新泽西州生物技术协会（自2021年起）、Duke Margolis Value Based Agreements Advisory Board、再生医学联盟（ARM）（自2018年起）和细胞与基因医学基金会（FCGM）（自2019年起）的成员。他是ARM和FCGM董事会执行委员会成员，并担任ARM董事会治理和运营委员会主席。Smith先生还是Ocugen, Inc.商业顾问委员会、威斯康星州麦迪逊市风险投资者有限责任公司投资咨询委员会以及弗吉尼亚州夏洛茨维尔焦点超声基金会细胞和基因治疗科学顾问委员会的成员。Smith先生在罗切斯特大学获得神经科学学士学位，在纽约州罗切斯特的罗切斯特大学William E. Simon工商管理研究生院获得金融和企业会计工商管理硕士学位。
- Robert Smith has been a member of the Board of Directors since March 2024. Mr. Smith is an accomplished biopharmaceutical executive who has driven commercial, financial, and operational success at leading pharmaceutical companies, including Pfizer Inc. (NYSE: PFE) and Wyeth Pharmaceuticals (formerly NYSE: WYE), for more than 35 years. Mr. Smith's extensive indtry expertise has been honed by decades of executive leadership roles in biness development, mergers and acquisitions, corporate and commercial strategy, and research and development. For the past eight years (May 2016 to January 2024), Mr. Smith served as Senior Vice President, Global Gene Therapy Biness of Pfizer and was responsible for managing and leading gene therapy and rare disease early commercial development activities in partnership with the rare disease research unit. He is a member of the Executive Committees of the ARM and FCGM Board of Directors and serves as the Chairman of the ARM Board's Governance and Operations Committee. Mr. Smith is also a member of the Biness Advisory Board of Ocugen, Inc., the Investment Advisory Committee for Venture Investors LLC, Madison, Wisconsin, and the Cell and Gene Therapy Scientific Advisory Board of the Foced Ultrasound Foundation based in Charlottesville, Virginia. Mr. Smith obtained a B.S. in Neuroscience from the University of Rochester and an M.B.A. in Finance and Corporate Accounting from the William E. Simon Graduate School of Biness Administration at the University of Rochester, Rochester, New York.
高管简历
中英对照 | 中文 | 英文- Leonard Mazur
Leonard Mazur是该公司的执行主席兼秘书，自2014年9月起担任董事会成员。Mazur先生还担任我们持有多数股权的子公司Novecite，Inc.的秘书，并为Novecite提供其他指导。Mazur先生是Akrimax Pharmaceuticals，LLC“；Akrimax”；的联合创始人兼副董事长，该公司是一家私人控股的制药公司，专门生产心血管和通用制药产品。Akrimax成立于2008年9月，在从主要制药公司收购药物的同时成功推出处方药。从2005年1月到2012年5月，Mazur先生共同创立并担任Triax Pharmaceuticals LLC（“；Triax”；）的首席运营官，这是一家专业制药公司，生产处方皮肤病药物。加入Triax之前，他从1995年到2005年担任Genesis Pharmaceutical，Inc.（“；Genesis”；）的创始人和首席执行官，该公司是一家皮肤科产品公司，通过皮肤科医生办公室销售其产品，并为主要制药公司共同推广产品。Mazur先生于2003年成功地将Genesis出售给Pierre Fabre，这是一家领先的制药公司。Mazur先生在Medicis Pharmaceutical Corporation担任执行Vice President、ICN Pharmaceuticals，Inc.担任Vice President、销售和市场营销、Knoll Pharma（巴斯夫公司的一个部门）和Cooper Laboratories，Inc.拥有丰富的销售、市场营销和业务发展经验。Mazur先生是Manor College的董事会成员，是Ellis Island Medal of Honor的获得者，之前是公司全资子公司LMB的董事会主席。Mazur先生从坦普尔大学（Temple University）获得学士学位和工商管理硕士学位，并曾在美国海军陆战队预备役部队服役。
Leonard Mazur is the Executive Chairman and Secretary of the Company and has been a member of the Board of Directors since September 2014 and in May 2022 became the Chief Executive Officer. Mr. Mazur also serves as and President and Chief Executive Officer and member of the board of directors of majority owned subsidiary, Citi Oncology, Inc. (Nasdaq: CTOR) ("Citi Oncology"), and as the Secretary of majority owned subsidiary, NoveCite, Inc. ("NoveCite"), and provides other guidance to Citi Oncology and NoveCite. From Augt 2021 to June 2025, Mr. Mazur served on the board of directors of Tharimmune, Inc. (formerly Hillstream BioPharma, Inc.) (Nasdaq: THAR), a pre clinical biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. Mr. Mazur was the co founder and Vice Chairman of Akrimax Pharmaceuticals, LLC ("Akrimax"), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products, from its founding in 2008 until its sale in 2018. From January 2005 to May 2012, Mr. Mazur co founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC ("Triax"), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. ("Genesis"), a dermatological products company that marketed its products through dermatologists' offices as ll as co promoting products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and biness development experience from his tenures at Medicis Pharmaceutical Corporation as Executive Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc. Mr. Mazur is a member of the Board of Trtees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previoly the Chairman of the board of directors of Leonard Meron Biosciences, Inc. ("LMB"), the Company's wholly owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from Temple University and has served in the U.S. Marine Corps Reserves.- Leonard Mazur是该公司的执行主席兼秘书，自2014年9月起担任董事会成员。Mazur先生还担任我们持有多数股权的子公司Novecite，Inc.的秘书，并为Novecite提供其他指导。Mazur先生是Akrimax Pharmaceuticals，LLC“；Akrimax”；的联合创始人兼副董事长，该公司是一家私人控股的制药公司，专门生产心血管和通用制药产品。Akrimax成立于2008年9月，在从主要制药公司收购药物的同时成功推出处方药。从2005年1月到2012年5月，Mazur先生共同创立并担任Triax Pharmaceuticals LLC（“；Triax”；）的首席运营官，这是一家专业制药公司，生产处方皮肤病药物。加入Triax之前，他从1995年到2005年担任Genesis Pharmaceutical，Inc.（“；Genesis”；）的创始人和首席执行官，该公司是一家皮肤科产品公司，通过皮肤科医生办公室销售其产品，并为主要制药公司共同推广产品。Mazur先生于2003年成功地将Genesis出售给Pierre Fabre，这是一家领先的制药公司。Mazur先生在Medicis Pharmaceutical Corporation担任执行Vice President、ICN Pharmaceuticals，Inc.担任Vice President、销售和市场营销、Knoll Pharma（巴斯夫公司的一个部门）和Cooper Laboratories，Inc.拥有丰富的销售、市场营销和业务发展经验。Mazur先生是Manor College的董事会成员，是Ellis Island Medal of Honor的获得者，之前是公司全资子公司LMB的董事会主席。Mazur先生从坦普尔大学（Temple University）获得学士学位和工商管理硕士学位，并曾在美国海军陆战队预备役部队服役。
- Leonard Mazur is the Executive Chairman and Secretary of the Company and has been a member of the Board of Directors since September 2014 and in May 2022 became the Chief Executive Officer. Mr. Mazur also serves as and President and Chief Executive Officer and member of the board of directors of majority owned subsidiary, Citi Oncology, Inc. (Nasdaq: CTOR) ("Citi Oncology"), and as the Secretary of majority owned subsidiary, NoveCite, Inc. ("NoveCite"), and provides other guidance to Citi Oncology and NoveCite. From Augt 2021 to June 2025, Mr. Mazur served on the board of directors of Tharimmune, Inc. (formerly Hillstream BioPharma, Inc.) (Nasdaq: THAR), a pre clinical biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. Mr. Mazur was the co founder and Vice Chairman of Akrimax Pharmaceuticals, LLC ("Akrimax"), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products, from its founding in 2008 until its sale in 2018. From January 2005 to May 2012, Mr. Mazur co founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC ("Triax"), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. ("Genesis"), a dermatological products company that marketed its products through dermatologists' offices as ll as co promoting products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and biness development experience from his tenures at Medicis Pharmaceutical Corporation as Executive Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc. Mr. Mazur is a member of the Board of Trtees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previoly the Chairman of the board of directors of Leonard Meron Biosciences, Inc. ("LMB"), the Company's wholly owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from Temple University and has served in the U.S. Marine Corps Reserves.
- Jaime Bartushak
Jaime Bartushak，2014年4月1日至2017年11月，Bartushak先生担任公司全资子公司Leonard-Meron Biosciences，Inc.的首席财务官。Bartushak先生是一位经验丰富的早期制药公司的财务专业人士，拥有超过20年的企业财务、业务发展、重组和战略规划经验。Bartushak先生于2014年成为LMB的创始人之一，并在其初创公司以及获得初始投资资本方面发挥了重要作用。在LMB工作之前的2014年，Bartushak先生帮助领导Precision Dermatology，Inc.出售给Valeant Pharmaceuticals International，Inc.。
Jaime Bartushak has served as Chief Financial Officer since November 2017, upon the acquisition of LMB by the Company. From April 1, 2014 until November 2017, Mr. Barthak served as Chief Financial Officer of LMB. In November 2022, he was also appointed Chief Biness Officer of the Company. Mr. Barthak also serves as Treasurer and Chief Financial Officer of majority owned subsidiary, Citi Oncology. Mr. Barthak is an experienced finance professional for early stage pharmaceutical companies, and has over 20 years of corporate finance, biness development, restructuring, and strategic planning experience. Mr. Barthak was one of the founders of LMB in 2014 and was instrumental in its startup as ll as in obtaining initial investment capital. In 2014, prior to his work at LMB, Mr. Barthak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc. (now Bach Health Companies Inc.). Mr. Barthak holds a Master of Science and Bachelor of Science from the New Jersey Institute of Technology.- Jaime Bartushak，2014年4月1日至2017年11月，Bartushak先生担任公司全资子公司Leonard-Meron Biosciences，Inc.的首席财务官。Bartushak先生是一位经验丰富的早期制药公司的财务专业人士，拥有超过20年的企业财务、业务发展、重组和战略规划经验。Bartushak先生于2014年成为LMB的创始人之一，并在其初创公司以及获得初始投资资本方面发挥了重要作用。在LMB工作之前的2014年，Bartushak先生帮助领导Precision Dermatology，Inc.出售给Valeant Pharmaceuticals International，Inc.。
- Jaime Bartushak has served as Chief Financial Officer since November 2017, upon the acquisition of LMB by the Company. From April 1, 2014 until November 2017, Mr. Barthak served as Chief Financial Officer of LMB. In November 2022, he was also appointed Chief Biness Officer of the Company. Mr. Barthak also serves as Treasurer and Chief Financial Officer of majority owned subsidiary, Citi Oncology. Mr. Barthak is an experienced finance professional for early stage pharmaceutical companies, and has over 20 years of corporate finance, biness development, restructuring, and strategic planning experience. Mr. Barthak was one of the founders of LMB in 2014 and was instrumental in its startup as ll as in obtaining initial investment capital. In 2014, prior to his work at LMB, Mr. Barthak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc. (now Bach Health Companies Inc.). Mr. Barthak holds a Master of Science and Bachelor of Science from the New Jersey Institute of Technology.
- Myron S. Czuczman
Myron Czuczman于2020年7月加入Citius。在受雇于我们之前，Czuczman博士曾担任Vice President，全球临床研究与开发，新基医药公司淋巴瘤/CLL治疗区域主管，他担任该职位长达五年。在制药行业工作之前，Czuczman博士在纽约布法罗的罗斯威尔公园癌症研究所（Roswell Park Cancer Institute）从事了二十多年的医学工作。Czuczman博士在匹兹堡大学（University of Pittsburgh）以优异成绩毕业后获得宾夕法尼亚州立大学医学院（Pennsylvania State University College of Medicine）的医学博士学位。
Myron S. Czuczman joined Citi Pharma as Chief Medical Officer in July 2020. Prior to his employment with Citi Pharma, Dr. Czuczman was Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL at Celgene Corporation, a position he held from June 2015 to January 2020. Prior to working in the pharmaceutical indtry, Dr. Czuczman practiced medicine for over two decades at Rosll Park Cancer Institute, an NCI designated comprehensive cancer center in Buffalo, NY, where he served as chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory. In addition to his extensive publications record, membership and leadership roles on national and international research organizations, and consulting and advisory to dozens of pharma companies, Dr. Czuczman also attained the positions of tenured Professor of Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and Professor of Oncology at Rosll Park Comprehensive Cancer Center. Dr. Czuczman received his medical degree from the Pennsylvania State University College of Medicine after graduating magna cum laude in Biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at ill Cornell North Shore University/MSKCC Program, follod by Medical Oncology/Hematology fellowship training at Memorial Sloan Kettering Cancer Center in New York City.- Myron Czuczman于2020年7月加入Citius。在受雇于我们之前，Czuczman博士曾担任Vice President，全球临床研究与开发，新基医药公司淋巴瘤/CLL治疗区域主管，他担任该职位长达五年。在制药行业工作之前，Czuczman博士在纽约布法罗的罗斯威尔公园癌症研究所（Roswell Park Cancer Institute）从事了二十多年的医学工作。Czuczman博士在匹兹堡大学（University of Pittsburgh）以优异成绩毕业后获得宾夕法尼亚州立大学医学院（Pennsylvania State University College of Medicine）的医学博士学位。
- Myron S. Czuczman joined Citi Pharma as Chief Medical Officer in July 2020. Prior to his employment with Citi Pharma, Dr. Czuczman was Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL at Celgene Corporation, a position he held from June 2015 to January 2020. Prior to working in the pharmaceutical indtry, Dr. Czuczman practiced medicine for over two decades at Rosll Park Cancer Institute, an NCI designated comprehensive cancer center in Buffalo, NY, where he served as chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory. In addition to his extensive publications record, membership and leadership roles on national and international research organizations, and consulting and advisory to dozens of pharma companies, Dr. Czuczman also attained the positions of tenured Professor of Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and Professor of Oncology at Rosll Park Comprehensive Cancer Center. Dr. Czuczman received his medical degree from the Pennsylvania State University College of Medicine after graduating magna cum laude in Biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at ill Cornell North Shore University/MSKCC Program, follod by Medical Oncology/Hematology fellowship training at Memorial Sloan Kettering Cancer Center in New York City.